SeraLab Overview

  • Founded
  • 1998
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Buyout/​LBO
  • Financing Rounds
  • 1

SeraLab General Information

Description

Developer of biologically manufactured components for drug development. The company controls and develops disease state matrices manufactured from human and animal blood, plasma and serum, used in drug discovery, compound development and clinical and research diagnostics, enabling scientists and biomedical researchers to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and the effects on disease processes.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Primary Industry
Distributors/Wholesale
Other Industries
Drug Discovery
Biotechnology
Acquirer
Primary Office
  • 209, Tower Bridge Business Centre
  • 46-48 East Smithfield
  • London E1W 1AW
  • England, United Kingdom
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

SeraLab Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore SeraLab‘s full profile, request access.

Request a free trial